ACUMEN PHARMACEUTICALS, INC.

Analyst Reco. Acumen Pharmaceuticals, Inc.

Equities

ABOS

US00509G2093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
3.16 ^USD	+0.96%		-9.71%	-17.71%

Apr. 04	Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	MT
Apr. 04	Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $8 Price Target	Dec. 12	MT
UBS Adjusts Acumen Pharmaceuticals Price Target to $15 From $16, Maintains Buy Rating	23-08-09	MT
BofA Securities Reinstates Acumen Pharmaceuticals at Buy With $14 Price Target	23-07-20	MT
In wait-and-see mode before Tesla and Netflix	23-07-17
Cantor Fitzgerald Starts Acumen Pharmaceuticals at Overweight With $13 Price Target	23-05-18	MT
Credit Suisse Lowers Acumen Pharmaceuticals' Price Target to $13 From $16, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	23-03-28	MT
Credit Suisse Trims Acumen Pharmaceuticals' Price Target to $16 From $17, Keeps Outperform Rating	22-11-15	MT
BTIG Adjusts Acumen Pharmaceuticals' Price Target to $22 From $15, Reiterates Buy Rating	22-10-05	MT
UBS Adjusts Acumen Pharmaceuticals Price Target to $16 From $27, Maintains Buy Rating	22-08-17	MT
BTIG Starts Acumen Pharmaceuticals at Buy With $15 Price Target	22-07-15	MT
HC Wainwright Initiates Coverage on Acumen Pharmaceuticals With Buy Rating, $15 Price Target	22-06-30	MT
Credit Suisse Lowers Acumen Pharmaceuticals' PT to $17 from $26 on Updated Assumptions for ACU193 Pricing, FY Model Updates; Keeps Outperform Rating	22-03-29	MT
Stifel Nicolaus Lowers Price Target for Acumen Pharmaceuticals to $17 From $27, Maintains Buy Rating	22-03-08	MT
BofA Securities Upgrades Acumen Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $14 From $16	22-01-21	MT
ACUMEN PHARMACEUTICALS : Credit Suisse Starts Acumen Pharmaceuticals at Outperform with $26 PT, Notes Sole Product's High-Risk, High-Return Potential	21-07-26	MT
ACUMEN PHARMACEUTICALS : Stifel Initiates Acumen Pharmaceuticals at Buy Rating With $27 Price Target	21-07-26	MT
ACUMEN PHARMACEUTICALS : UBS Starts Acumen Pharmaceuticals at Buy With $27 Price Target	21-07-26	MT
ACUMEN PHARMACEUTICALS : BofA Securities Starts Acumen Pharmaceuticals at Neutral With $20 Price Target	21-07-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer